MIRM
Mirum Pharmaceuticals Inc.
$99.56
-$1.11(-1.10%)
57
Overall
40
Value
60
Tech
71
Quality
Market Cap
$3.86B
Volume
79.60K
52W Range
$42.89 - $112.00
Target Price
$143.45
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | -- | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M | ||
| Total Revenue | -- | -- | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | $1.9M | $12.4M | $47.0M | $81.6M | -- | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | -- | $17.2M | $64.7M | $186.4M | $336.9M | $521.3M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $54.7M | $104.3M | $192.6M | $195.9M | $295.5M | $424.5M | $543.4M | ||
| Research & Development | $43.0M | $81.6M | $131.4M | $106.8M | $102.6M | $140.6M | $186.2M | ||
| Research Expense | $43.0M | $81.6M | $131.4M | $106.8M | $102.6M | $140.6M | $186.2M | ||
| Selling, General & Administrative | $11.8M | $22.7M | $59.2M | $89.1M | $145.9M | $202.2M | $257.0M | ||
| Selling & Marketing Expenses | -- | $600.0K | $9.2M | $4.0M | $6.3M | $11.5M | -- | ||
| General & Administrative Expenses | $11.8M | $22.7M | $59.2M | $89.1M | $145.9M | $202.2M | $257.0M | ||
| Promotion & Advertising | -- | $600.0K | $9.2M | -- | -- | -- | -- | ||
| Salaries & Wages | $-6.1M | -- | $100.0K | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | $300.0K | $300.0K | $300.0K | $500.0K | -- | ||
| Depreciation & Amortization | -- | -- | $300.0K | -- | -- | -- | -- | ||
| Amortization | -- | -- | $300.0K | $2.9M | $11.6M | $25.2M | -- | ||
| Other Operating Expenses | $-1.4M | $-2.5M | $-1.9M | -- | -- | -- | -- | ||
| OPERATING INCOME | |||||||||
| Operating income | $-54.7M | $-104.3M | $-173.4M | $-131.2M | $-109.2M | $-87.6M | $-22.1M | ||
| EBITDA | $-52.5M | $-102.4M | $-169.7M | $-122.9M | $-135.4M | $-47.3M | $18.9M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $16.0M | $15.1M | $14.3M | $14.4M | ||
| Intinc | $2.2M | $1.6M | $366.0K | $3.9M | $13.7M | $13.8M | $12.7M | ||
| Net Non-Operating Interest Income/Expense | $2.2M | $1.6M | $366.0K | $12.1M | $-1.4M | $-519.0K | $-1.7M | ||
| Other Income/Expense | $21.0K | $192.0K | $582.0K | $1.3M | $51.9M | $-1.2M | $-2.4M | ||
| Other Special Charges | $-21.0K | $-192.0K | $-582.0K | $365.0K | $-51.9M | $1.2M | $2.4M | ||
| SPECIAL ITEMS | |||||||||
| Special Income Charges | -- | -- | $-732.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-52.5M | $-102.9M | $-170.6M | $-126.1M | $-147.3M | $-72.6M | $-7.0M | ||
| Pre-Tax Income | $-52.5M | $-103.3M | $-84.0M | $-142.1M | $-162.4M | $-86.9M | $-21.4M | ||
| INCOME TAX | |||||||||
| Tax Provision | $21.0K | $6.0K | $37.0K | $-6.4M | $991.0K | $1.0M | $1.9M | ||
| NET INCOME | |||||||||
| Net Income | $-52.6M | $-103.3M | $-84.0M | $-135.7M | $-163.4M | $-87.9M | $-23.4M | ||
| Net Income (Continuing Operations) | $-52.6M | $-102.9M | $-170.6M | $-135.7M | $-163.4M | $-87.9M | $-23.4M | ||
| Net Income (Discontinued Operations) | $-52.6M | $-103.3M | $-84.0M | $-135.7M | $-163.4M | $-87.9M | $-23.4M | ||
| Net Income (Common Stockholders) | $-52.6M | $-102.9M | $-84.0M | $-135.7M | $-163.4M | $-87.9M | $-23.4M | ||
| Normalized Income | $-41.5M | $-81.6M | $-65.6M | -- | -- | -- | $-21.2M | ||
| TOTALS | |||||||||
| Total Expenses | $54.7M | $104.3M | $194.5M | $208.3M | $295.5M | $424.5M | $543.4M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $11.5M | $25.3M | $30.3M | $33.8M | $40.9M | $47.5M | $50.2M | ||
| Average Shares Outstanding (Diluted) | $11.5M | $25.3M | -- | $34.0M | $40.9M | $47.5M | $50.2M | ||
| Shares Outstanding | $25.4M | $30.4M | $31.7M | $38.0M | $47.0M | $49.0M | $60.3M | ||
| Basic EPS | -- | $-4.09 | $-2.77 | $-4.01 | $-4 | $-1.85 | $-0.47 | ||
| Basic EPS (Continuing Operations) | -- | $-4.09 | $-2.77 | $-4.01 | $-4 | $-1.85 | $-0.47 | ||
| Diluted EPS | $-4.58 | $-4.09 | $-2.77 | $-4.02 | $-4 | $-1.85 | $-0.47 | ||
| Diluted EPS (Continuing Operations) | $-4.58 | -- | -- | $-4.02 | $-4 | $-1.85 | $-0.47 | ||
| OTHER METRICS | |||||||||
| Excise Taxes | -- | -- | -- | $-906.0K | -- | -- | -- | ||
| Other Gand A | $11.8M | $22.7M | $59.2M | $89.1M | $145.9M | $202.2M | $257.0M | ||
| Rent And Landing Fees | -- | -- | -- | $-906.0K | -- | -- | -- | ||
| Othspecchg | -- | -- | $732.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MIRM | $99.56 | -1.1% | 79.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Mirum Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW